Connect Biopharma Holdings (Connect Biopharma Holdings) EV-to-EBIT : 0.75 (As of Apr. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Connect Biopharma Holdings's Enterprise Value is $-44.35 Mil. Connect Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.36 Mil. Therefore, Connect Biopharma Holdings's EV-to-EBIT for today is 0.75.

The historical rank and industry rank for Connect Biopharma Holdings's EV-to-EBIT or its related term are showing as below:

CNTB' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.11 Med: 0 Max: 1.11
Current: 0.75

During the past 5 years, the highest EV-to-EBIT of Connect Biopharma Holdings was 1.11. The lowest was -0.11. And the median was 0.00.

CNTB's EV-to-EBIT is ranked better than
70.65% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs CNTB: 0.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Connect Biopharma Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $-53.17 Mil. Connect Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.36 Mil. Connect Biopharma Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 111.65%.

Connect Biopharma Holdings EV-to-EBIT Historical Data

The historical data trend for Connect Biopharma Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings EV-to-EBIT Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-0.08

0.88

0.90

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial				-0.08	-	0.88	-	0.90

Competitive Comparison of Connect Biopharma Holdings's EV-to-EBIT

For the Biotechnology subindustry, Connect Biopharma Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's EV-to-EBIT falls into.

Connect Biopharma Holdings EV-to-EBIT Calculation

Connect Biopharma Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-44.350	/	-59.36
	=	0.75

Connect Biopharma Holdings's current Enterprise Value is $-44.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Connect Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.36 Mil.

Connect Biopharma Holdings (NAS:CNTB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Connect Biopharma Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-59.36	/	-53.16646
	=	111.65 %

Connect Biopharma Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $-53.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Connect Biopharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.36 Mil.

Connect Biopharma Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.